These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Sustained weight loss after duodenal-jejunal bypass liner treatment in patients with body mass index below, but not above 35 kg/m Boonchaya-Anant P; Bueter M; Gubler C; Gerber PA Clin Obes; 2023 Feb; 13(1):e12561. PubMed ID: 36239531 [TBL] [Abstract][Full Text] [Related]
17. The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids. Glaysher MA; Ward J; Aldhwayan M; Ruban A; Prechtl CG; Fisk HL; Chhina N; Al-Najim W; Smith C; Klimowska-Nassar N; Johnson N; Falaschetti E; Goldstone AP; Miras AD; Byrne JP; Calder PC; Teare JP Clin Nutr; 2021 Apr; 40(4):2343-2354. PubMed ID: 33131909 [TBL] [Abstract][Full Text] [Related]
18. Influence of glucometric 'dynamical' variables on duodenal-jejunal bypass liner (DJBL) anthropometric and metabolic outcomes. Colás A; Varela M; Mraz M; Novak D; Cuesta-Frau D; Vigil L; Benes M; Pelikanova T; Haluzik M; Burda V; Vargas B Diabetes Metab Res Rev; 2020 May; 36(4):e3287. PubMed ID: 31916665 [TBL] [Abstract][Full Text] [Related]
19. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes. Jirapinyo P; Haas AV; Thompson CC Diabetes Care; 2018 May; 41(5):1106-1115. PubMed ID: 29678867 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years. Quezada N; Muñoz R; Morelli C; Turiel D; Hernández J; Pimentel F; Escalona A Surg Endosc; 2018 Jan; 32(1):260-267. PubMed ID: 28664427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]